Amit et al. (2024) demonstrated RT and MSLN-targeting CAR-T cell therapy, combined in a PDAC model, have been demonstrated to elevate MSLN expression in cancer cells, enhance CAR-T cell infiltration into malignancies, alter immunosuppressive M1 macrophages to anti-cancer M1 macrophages and minimize MDSCs. The gene discussed is MSLN; the disease is cancer.